Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba92c0ca069935688b6d532de09efa66d> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba92c0ca069935688b6d532de09efa66d NCIT_P378 "NCI" @default.
- Ba92c0ca069935688b6d532de09efa66d type Axiom @default.
- Ba92c0ca069935688b6d532de09efa66d annotatedProperty IAO_0000115 @default.
- Ba92c0ca069935688b6d532de09efa66d annotatedSource NCIT_C189979 @default.
- Ba92c0ca069935688b6d532de09efa66d annotatedTarget "The hydrochloriden salt form of emavusertib, an orally bioavailable, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with potential antineoplastic, immunomodulating and anti-inflammatory activities. Upon oral administration, emavusertib targets, binds to, and blocks the kinase activity of IRAK4. This inhibits IRAK4-mediated signaling, prevents the activation of IRAK4-mediated nuclear factor-kappa B (NF-kB) signaling and decreases the expression of inflammatory cytokines and certain pro-survival factors. This inhibits proliferation of IRAK4-overactivated tumor cells, which are found in cells harboring MYD88 activating mutations or those with overactivated toll-like receptor (TLR) pathways. In addition, CA-4948 may inhibit inflammation and immune-mediated cell destruction in inflammatory and auto-immune diseases where TLR or interleukin 1 receptor (IL-1R) signaling is overactivated and MYD88 is dysregulated. IRAK4, a serine/threonine-protein kinase that plays a key role in both the TLR and IL-1R signaling pathways, is activated though the adaptor protein MYD88 and links the TLR and IL-1R signaling pathway to the NF-kB pathway." @default.